
SOM Biotech is a trailblazer in the biotech industry, and its innovative approach is revolutionizing the way we approach healthcare and disease treatment. SOM Biotech's cutting-edge technology has the potential to transform lives.
The company's focus on gene editing and RNA-based therapies has led to significant breakthroughs in the field. SOM Biotech's scientists have made groundbreaking discoveries in the realm of CRISPR-Cas9 gene editing.
Their work has far-reaching implications for the treatment of genetic diseases and has the potential to improve the human condition. SOM Biotech's commitment to advancing biotechnology is unwavering and has earned the company recognition in the scientific community.
By pushing the boundaries of what is thought possible, SOM Biotech is paving the way for a new era of biotechnology research and development.
You might like: Unity Biotechnology
Awards and Recognition
SOM Biotech has received several prestigious awards for its innovative work in biotechnology. The company won the Entrepreneur XXI Award in 2013 for its growth in the biotechnology category.
This award is recognized as one of the most consolidated initiatives to support entrepreneurship in Spain. It was promoted by La Caixa, the Spanish Ministry of Industry, Energy and Tourism, and ENISA.
In 2018, SOM Biotech received the XXI Century Technology Award for its commitment to achieving medical advances for patients with orphan diseases and its exponential growth that year. The company's dedication to this cause earned it this well-deserved recognition.
SOM Biotech was also included in the list of Spanish startups and scaleups to watch in 2020 and 2021, published by Sifted, a Financial Times-backed company.
Financing and Funding
SOM Biotech has secured significant funding to support its growth and development.
In 2016, the company raised €2 million in a round of funding with 18 international investors from various countries.
These investors came from countries such as Monaco, the United Kingdom, Poland, the Republic of Czech, the United States, South Korea, Hong Kong, India, and Spain.
You might like: Biotech Startup Funding
The company led this operation, along with a European family-owned company with a long tradition in the pharmaceutical sector.
In 2019, SOM Biotech closed another financing round, this time securing 7 million euros.
This successful funding has likely enabled the company to further develop its operations and pursue new opportunities.
AI Drug Discovery
SOM Biotech is an AI drug discovery and development company that's making waves in the industry. They're focused on developing therapies for orphan indications through their proprietary AI-based drug discovery technology.
Their technology, SOM PRO, is a unique computational tool that efficiently applies AI in drug discovery and development. It combines efficient computational algorithms with thorough analysis and design carried out by experts in biochemistry, molecular biology, and computational chemistry.
This approach allows SOM Biotech to acquire an extensive list of high-grade lead candidate targets and hits, making the process shorter, cheaper, and more efficient compared to traditional R&D processes.
Suggestion: Cambridge Antibody Technology
Products & Services
SOM Biotech is at the forefront of AI-driven drug discovery, leveraging their proprietary technology, SOMAI PRO, to identify molecular field maps and accelerate the development of new treatments.
This AI-based technology has been successfully applied in various therapeutic areas, including neurology and rare diseases.
SOM Biotech's clinical pipeline is robust, with programs for TTR Amyloidosis, chorea in Huntington's disease, and Phenylketonuria, among others.
One notable example is SOM3355, a treatment for chorea in Huntington's disease, which has completed a successful phase IIa clinical trial with no serious adverse events.
The company's commitment to innovation is evident in its preclinical pipeline, which includes programs for Niemann Pick Type C, Parkinson's, and Tay-Sachs disease.
Here are some of the key products and services offered by SOM Biotech:
- SOM1311: a small molecule pharmacological chaperone for the treatment of Phenylketonuria
- SOM0208: a small molecule for the treatment of Niemann–Pick C disease
- SOM0044: a small molecule for the treatment of Parkinson’s disease
- SOM0777: a compound licensed to Argon Pharma for the treatment of glioblastoma
- SOM0226: a compound granted orphan drug designation by the FDA for the treatment of TTR Amyloidosis
AI Drug Discovery
SOM Biotech is an AI drug discovery and development company focused on developing therapies for orphan indications using their proprietary AI-based drug discovery technology.
The company's AI technology has been clinically validated through two programs with positive Clinical Phase 2a results, providing proof-of-concept for their AI drug discovery technology.
Here's an interesting read: Meyer Brothers Drug Company
SOM Biotech's AI technology, SOM PRO, efficiently applies AI in drug discovery and development by uniting computational algorithms with thorough analysis and design carried out by experts in biochemistry, molecular biology, and computational chemistry.
This approach allows for the acquisition of high-grade lead candidate targets and hits, making the entire process shorter, cheaper, and more efficient compared to traditional research and development.
With SOM PRO, SOM Biotech can apply their AI technology to any therapeutic area, not just orphan diseases, giving them a clear competitive advantage.
The company's AI technology has also been experimentally validated from medical, scientific, and business perspectives, ensuring the accuracy and reliability of their results.
SOM Biotech's development unit works closely with computational chemists to plan screening procedures tailored to each project's unique needs, resulting in high-quality results and a faster drug discovery process.
Team and Expertise
At SOM Biotech, the development team is the backbone of the company's success. They work closely with computational chemists to plan screening procedures tailored to each project's specific needs.
This collaborative approach allows the teams to outline and enhance each parameter essential for effective project performance. The result is the accurate selection of the most suitable information used in the process.
SOM Biotech's development unit is highly skilled at recovering high-quality information from extensive databases. This enables the company to fast-track the drug discovery process.
By transforming the current R&D model, SOM Biotech is revolutionizing the way new medicines are developed.
Featured Images: pexels.com


